Novo Nordisk Inks A $2.1 Billion Deal To Develop Next Generation Obesity Pills

The Danish drugmaker is collaborating with Vivtex, cofounded by billionaire Robert Langer, to quickly iterate oral versions ...
STAT

Novo Nordisk strikes deal with U.S. startup to develop oral obesity, diabetes drugs

Novo Nordisk announced it had signed a deal with Vivtex, a biotech co-founded by MIT professor Robert Langer, to develop oral ...

Novo bets up to $2.1B in Vivtex deal for oral obesity and diabetes drugs

Novo Nordisk (NVO) stock is in focus as the company teams up with Vivtex in a $2.1B deal to develop next-gen oral biologics for obesity and diabetes. Read more here.
GEN - Genetic Engineering and Biotechnology News

Omics in Orlando: A Video Report from AGBT, Day One

Reporting from AGBT in Orlando, Julianna LeMieux checks in with Kevin Davies to review key announcements from the meeting.

Royal Biologics Announces Strategic Partnership with Jellagen (UK) to Bring Jellyfish-Derived Collagen Type Zero to the U.S. Regenerative Medicine Market

Royal Biologics is a global, clinically driven biologics and wound care company committed to delivering innovative regenerative solutions. The company focuses on patient-centered outcomes through ...